• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Valeritas touts cost savings, real-world outcomes with V-Go insulin pump

May 24, 2017 By Sarah Faulkner

ValeritasIn a retrospective analysis of 86 diabetic patients who switched from multiple daily insulin injections to the V-Go insulin pump, Valeritas (NSDQ:VLRX) reported this week that use of its device led to a 44% reduction in total daily insulin dose per patient.

A drastic cut to a patient’s daily insulin dose and improvement to their blood sugar levels are outcomes that Scott Abbott, director of medical development at Valeritas, has come to expect with the company’s device.

“We’ve seen this in almost every study that has been done using the V-Go insulin delivery device,” Abbott told Drug Delivery Business News.

Not only did the pump cut each patient’s daily dose and reduce blood sugar levels, it was also associated with direct pharmacy cost savings of $146.00±$378.60 per patient per month, according to data presented at the annual meeting of the International Society for Pharmacoeconomics and Outcomes Research.

In a prospective clinical trial of the V-Go wearable pump, the company compared real-world use of its device in 169 patients with Type II diabetes to 246 patients treated with multiple daily doses of insulin.

Patients who used the V-Go pump experienced improved diabetes treatment outcomes, but treatment was also cheaper, according to the data. The mean per-patient-per-day cost of diabetes treatment was $32.60 for standard treatment compared to $30.59 for the V-Go treatment groups.

Abbott said that having this pharmaco-economic data is crucial, especially amid growing concern over the price of insulin.

“It’s important because you want a treatment that is effective and safe and treats the underlying condition, but also you want to do it in an economically sound manner,” he said.

V-Go is largely reimbursed through pharmacy benefit managers and Abbott said that payer and managed care companies are seeking data that show how the device could impact their pharmacy budgets.

Abbott also pointed out that enrolling patients into a real-world study with minimal inclusion/exclusion criteria can help ensure that the trial’s outcomes aren’t stifled by design.

“It provides a more realistic environment as to how treatments perform in a setting that is not run by a clinical study,” he said.

Valeritas’ wearable insulin pump won 510(k) clearance from the FDA in 2010 and CE Mark approval in the European Union the following year. Since then, executive VP & chief financial officer Erick Lucera said the company’s commercial strategy has evolved.

“One of the things that we’ve done is we’ve changed our marketing from a low touch, high reach where we were basically reaching out to a lot of doctors, dropping off samples and leaving. Now, we’re becoming a partner with the physicians,” Lucera said.

The Bridgewater, N.J.-based company is developing its next product iteration, called the V-Go Link, which it hopes will enable connectivity between a smart phone and its V-Go pump to track patient use.

Lucera said the V-Go Link will aim to help physicians better understand how much insulin their patients are regularly taking, since relying on patients to self-report their insulin intake is flawed.

“We think it’s a tremendous benefit in terms of increased patient compliance and getting the patient to goal soon rather than later,” he said.

The company has working prototypes of the V-Go Link and said it expects the product to be on the market in a year and a half.

Filed Under: Diabetes, Drug-Device Combinations, Featured, Pharmaceuticals Tagged With: Valeritas Inc.

IN CASE YOU MISSED IT

  • Medtronic to separate Diabetes business unit
  • Tandem Diabetes Care wins CE mark for Mobi insulin pump with Control-IQ+ technology
  • Glooko adds chief strategy officer to chief medical officer’s title
  • Cordis launches 10,000-patient registry for drug-eluting balloon
  • Senseonics opens $50M public offering, $25M private placement with Abbott

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS